Cortese I, Reich DS, Nath A. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol. 2021;17:37–51.

PubMed  Google Scholar 

Nakamichi K, Miura Y, Shimokawa T, Takahashi K, Suzuki T, Funata N, et al. Nationwide laboratory surveillance of progressive multifocal leukoencephalopathy in Japan: Fiscal years 2011–2020. Viruses. 2023;15:968.

CAS  PubMed  PubMed Central  Google Scholar 

Schweitzer F, Laurent S, Cortese I, Fink GR, Silling S, Skripuletz T, et al. Progressive multifocal leukoencephalopathy. Neurology. 2023;101:700–13.

CAS  PubMed  PubMed Central  Google Scholar 

Dong-Si T, Richman S, Wattjes MP, Wenten M, Gheuens S, Philip J, et al. Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann Clin Transl Neurol. 2014;1:755–64.

PubMed  PubMed Central  Google Scholar 

Baldassari LE, Wattjes MP, Cortese ICM, Gass A, Metz I, Yousry T, et al. The neuroradiology of progressive multifocal leukoencephalopathy: a clinical trial perspective. Brain. 2022;145:426–40.

PubMed  Google Scholar 

Ferenczy MW, Marshall LJ, Nelson CDS, Atwood WJ, Nath A, Khalili K, et al. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev. 2012;25:471–506.

CAS  PubMed  PubMed Central  Google Scholar 

Ault GS, Stoner GL. Human polyomavirus JC promoter/enhancer rearrangement patterns from progressive multifocal leukoencephalopathy brain are unique derivatives of a single archetypal structure. J Gen Virol. 1993;74:1499–507.

CAS  PubMed  Google Scholar 

Yogo Y, Zhong S, Shibuya A, Kitamura T, Homma Y. Transcriptional control region rearrangements associated with the evolution of JC polyomavirus. Virology. 2008;380:118–23.

CAS  PubMed  Google Scholar 

Shishido-Hara Y. Progressive multifocal leukoencephalopathy and promyelocytic leukemia nuclear bodies: a review of clinical, neuropathological, and virological aspects of JC virus-induced demyelinating disease. Acta Neuropathol. 2010;120:403–17.

PubMed  PubMed Central  Google Scholar 

Major EO, Yousry TA, Clifford DB. Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. Lancet Neurol. 2018;17:467–80.

CAS  PubMed  Google Scholar 

White MK, Khalili K. Pathogenesis of progressive multifocal leukoencephalopathy—revisited. J Infect Dis. 2011;203:578–86.

PubMed  PubMed Central  Google Scholar 

Wharton KA, Quigley C, Themeles M, Dunstan RW, Doyle K, Cahir-McFarland E, et al. JC Polyomavirus abundance and distribution in progressive multifocal leukoencephalopathy (PML) brain tissue implicates myelin sheath in intracerebral dissemination of infection. PLoS ONE. 2016;11: e0155897.

PubMed  PubMed Central  Google Scholar 

Nakamichi K, Shimokawa T. Database and statistical analyses of transcription factor binding sites in the non-coding control region of JC virus. Viruses. 2021;13:2314.

CAS  PubMed  PubMed Central  Google Scholar 

Wilczek MP, Pike AMC, Craig SE, Maginnis MS, King BL. Rearrangement in the hypervariable region of JC Polyomavirus genomes isolated from patient samples and impact on transcription factor-binding sites and disease outcomes. Int J Mol Sci. 2022;23:5699.

CAS  PubMed  PubMed Central  Google Scholar 

Joly M, Conte C, Cazanave C, Le Moing V, Tattevin P, Delobel P, et al. Progressive multifocal leukoencephalopathy: epidemiology and spectrum of predisposing conditions. Brain. 2023;146:349–58.

PubMed  Google Scholar 

Pavlovic D, Patel MA, Patera AC, Peterson I. T cell deficiencies as a common risk factor for drug associated progressive multifocal leukoencephalopathy. Immunobiology. 2018;223:508–17.

CAS  PubMed  Google Scholar 

Ho P-R, Koendgen H, Campbell N, Haddock B, Richman S, Chang I. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017;16:925–33.

CAS  PubMed  Google Scholar 

Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870–80.

CAS  PubMed  Google Scholar 

Bartsch T, Rempe T, Leypoldt F, Riedel C, Jansen O, Berg D, et al. The spectrum of progressive multifocal leukoencephalopathy: a practical approach. Eur J Neurol. 2019;26:566.

CAS  PubMed  Google Scholar 

Miskin DP, Herman ST, Ngo LH, Koralnik IJ. Predictors and characteristics of seizures in survivors of progressive multifocal leukoencephalopathy. J Neurovirol. 2016;22:464–71.

PubMed  Google Scholar 

Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ, et al. PML diagnostic criteria. Neurology. 2013;80:1430–8.

PubMed  PubMed Central  Google Scholar 

Cortese I, Muranski P, Enose-Akahata Y, Ha S-K, Smith B, Monaco M, et al. Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N Engl J Med. 2019;380:1597–605.

CAS  PubMed  Google Scholar 

Carson KR, Newsome SD, Kim EJ, Wagner-Johnston ND, von Geldern G, Moskowitz CH, et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer. 2014;120:2464–71.

CAS  PubMed  Google Scholar 

Pavlovic D, Patera AC, Nyberg F, Gerber M, Liu M, for the Progressive Multifocal Leukeoncephalopathy Consortium. Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord. 2015;8:255–73.

Sano Y, Nakano Y, Omoto M, Takao M, Ikeda E, Oga A, et al. Rituximab-associated progressive multifocal leukoencephalopathy derived from non-Hodgkin lymphoma: Neuropathological findings and results of mefloquine treatment. Intern Med. 2015;54:965–70.

CAS  PubMed  Google Scholar 

Berger JR, Pall L, Lanska D, Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol. 1998;4:59–68.

CAS  PubMed  Google Scholar 

Lima MA, Bernal-Cano F, Clifford DB, Gandhi RT, Koralnik IJ. Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy. J Neurol Neurosurg Psychiatry. 2010;81:1288–91.

CAS  PubMed  Google Scholar 

Anand P, Hotan GC, Vogel A, Venna N, Mateen FJ. Progressive multifocal leukoencephalopathy. Neurol Neuroimmunol Neuroinflamm [Internet]. 2019;6. Available from: https://doi.org/10.1212/nxi.0000000000000618

Vermersch P, Kappos L, Gold R, Foley JF, Olsson T, Cadavid D, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology. 2011;76:1697–704.

CAS  PubMed  Google Scholar 

Maas RPPWM, Muller-Hansma AHG, Esselink RAJ, Murk J-L, Warnke C, Killestein J, et al. Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases. J Neurol. 2016;263:2004–21.

Filippi M, Preziosa P, Banwell BL, Barkhof F, Ciccarelli O, De Stefano N, et al. Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. Brain. 2019;142:1858–75.

PubMed  PubMed Central  Google Scholar 

Bauer J, Gold R, Adams O, Lassmann H. Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS). Acta Neuropathol. 2015;130:751–64.

CAS  PubMed  Google Scholar 

Yousry TA, Pelletier D, Cadavid D, Gass A, Richert ND, Radue E-W, et al. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2012;72:779–87.

CAS  PubMed  Google Scholar 

Wijburg MT, Witte BI, Vennegoor A, Roosendaal SD, Sanchez E, Liu Y, et al. MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance. J Neurol Neurosurg Psychiatry. 2016;87:1138–45.

PubMed  Google Scholar 

Wattjes MP, Vennegoor A, Mostert J, van Oosten BW, Barkhof F, Killestein J. Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place? J Neurol. 2014;261:1139–43.

CAS  PubMed  Google Scholar 

Hodel J, Bapst B, Outteryck O, Verclytte S, Deramecourt V, Benadjaoud MA, et al. Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathy. Mult Scler. 2018;24:1902–8.

CAS  PubMed  Google Scholar 

Wattjes MP, Verhoeff L, Zentjens W, Killestein J, van Munster ET, Barkhof F, et al. Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation? J Neurol Neurosurg Psychiatry. 2013;84:1176–7.

PubMed  Google Scholar 

Wüthrich C, Dang X, Westmoreland S, McKay J, Maheshwari A, Anderson MP, et al. Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons. Ann Neurol. 2009;65:742–8.

PubMed  PubMed Central  Google Scholar 

Wüthrich C, Koralnik IJ. Frequent infection of cortical neurons by JC virus in patients with progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol. 2012;71:54–65.

PubMed